Ricco J B, Thanh Phong L, Belmonte R, Schneider F, Valagier A, Illuminati G, Regnault De La Mothe G
Vascular Surgery Department, Jean Bernard Hospital University of Poitiers, Poitiers, France -
J Cardiovasc Surg (Torino). 2013 Dec;54(6):719-27.
This review considers the role of the different revascularization strategies in patients with chronic limb ischemia (CLI) and reveals that clinical evidence guiding therapeutic decision-making in CLI is poor and only careful basic recommendations can be made. For diffuse aortoiliac disease with occlusion of the aorta, aortobifemoral bypass remains the best option if the patient is fit for open surgery. Unilateral iliac occlusion should be treated by primary stenting, but an iliofemoral bypass may be the best option when the disease extends down to the common and deep femoral arteries. For infrainguinal revascularisation, bypass using the saphenous vein remains the best option for patients with occlusion of the superficial femoral artery >25 cm and for patients with multiple occlusions of the infrapopliteal arteries. In the absence of leg veins, arm veins should be used. Prosthetic grafts are the last option. Endovascular techniques are recommended in patients with short arterial lesions and limited life expectancy <2 years. Finally some patients with CLI are best treated by primary amputation. In conclusion, this review demonstrates that neither an endo- first nor a bypass-first attitude is appropriate in patients with CLI and suggests that these patients should be cared for by specialists in a multidisciplinary center in order to preserve their life and limbs, to conduct clinical trials and to control costs.
本综述探讨了不同血管重建策略在慢性肢体缺血(CLI)患者中的作用,结果显示,指导CLI治疗决策的临床证据不足,只能给出谨慎的基本建议。对于合并主动脉闭塞的弥漫性主髂动脉疾病,若患者适合开放手术,主动脉双股动脉旁路移植术仍是最佳选择。单侧髂动脉闭塞应首选支架置入治疗,但当病变延伸至股总动脉和股深动脉时,髂股动脉旁路移植术可能是最佳选择。对于股腘以下血管重建,大隐静脉旁路移植术仍是股浅动脉闭塞长度>25 cm以及腘下动脉多处闭塞患者的最佳选择。若腿部静脉不可用,应使用手臂静脉。人工血管是最后的选择。对于动脉病变较短且预期寿命<2年的患者,建议采用血管腔内技术。最后,一些CLI患者首选截肢治疗。总之,本综述表明,对于CLI患者,“腔内优先”或“旁路优先”的态度均不合适,并建议这些患者应由多学科中心的专科医生进行治疗,以挽救其生命和肢体、开展临床试验并控制成本。